Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seroquel on Glucose Metabolism
NCT00214578Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2004
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 4, randomised, open-label trial of quetiapine in schizophrenia (3 arms), sponsored by AstraZeneca. Primary endpoint: Safety and tolerability profile of quetiapine on glucose metabolism at 6 months. Started Apr 2004; status: completed.
02
Drugs
quetiapine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00214578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00214578.